2-Hydroxy-2-(10-hydroxy-1,5,14,18,22,22,26-heptamethyl-27-oxaheptacyclo[15.13.0.02,14.05,13.06,11.018,28.021,26]triaconta-6,8,10-trien-7-yl)acetic acid

• 分子结构分类: 有机化合物 - 苯类化合物 - 芴
• 英文名称: 2-Hydroxy-2-(10-hydroxy-1,5,14,18,22,22,26-heptamethyl-27-oxaheptacyclo[15.13.0.02,14.05,13.06,11.018,28.021,26]triaconta-6,8,10-trien-7-yl)acetic acid
• 英文别名: 2-hydroxy-2-(10-hydroxy-1,5,14,18,22,22,26-heptamethyl-27-oxaheptacyclo[15.13.0.02,14.05,13.06,11.018,28.021,26]triaconta-6,8,10-trien-7-yl)acetic acid
• 化学式: C₃₈H₅₆O₅
• 分子量: 592.8
• InChiKey: NAKUKBFDSKFFRM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  9.2
• 重原子数：
  43
• 可旋转键数：
  2
• 环数：
  7.0
• sp3杂化的碳原子比例：
  0.82
• 拓扑面积：
  87
• 氢给体数：
  3
• 氢受体数：
  5

文献信息

• Method for treating cancer using chemokine antagonists
  申请人：Syntrix Biosystems Inc.

  公开号：US10660909B2

  公开（公告）日：2020-05-26

  What is described is a method for treating cancer in a patient in need of such treatment through the use of an antagonist to CXCR1 and/or CXCR2 receptors by administering a therapeutically effective amount of an antagonist of CXCR1 and/or CXCR2, or pharmaceutical compositions thereof, either alone as monotherapy, or in combination with at least one other anticancer therapy.

  所描述的是一种通过使用 CXCR1 和/或 CXCR2 受体拮抗剂治疗需要此类治疗的患者癌症的方法，其方法是施用治疗有效量的 CXCR1 和/或 CXCR2 拮抗剂或其药物组合物，既可单独作为单一疗法，也可与至少一种其他抗癌疗法联合使用。
• METHOD FOR TREATING CANCER USING CHEMOKINE ANTAGONISTS
  申请人：Syntrix Biosystems Inc.

  公开号：US20180177808A1

  公开（公告）日：2018-06-28

  What is described is a method for treating cancer in a patient in need of such treatment through the use of an antagonist to CXCR1 and/or CXCR2 receptors by administering a therapeutically effective amount of an antagonist of CXCR1 and/or CXCR2, or pharmaceutical compositions thereof, either alone as monotherapy, or in combination with at least one other anticancer therapy.
• [EN] METHOD FOR TREATING CANCER USING CHEMOKINE ANTAGONISTS ALONE OR IN COMBINATION<br/>[FR] MÉTHODE DE TRAITEMENT DU CANCER À L'AIDE D'ANTAGONISTES DE CHIMIOKINE SEULS OU EN COMBINAISON
  申请人：SYNTRIX BIOSYSTEMS INC

  公开号：WO2019165315A1

  公开（公告）日：2019-08-29

  What is described is a method for treating cancer in a patient in need of such treatment through the use of an antagonist to CXCR1 and/or CXCR2 receptors by administering a therapeutically effective amount of an antagonist of CXCR1 and/or CXCR2, or pharmaceutical compositions thereof, either alone as monotherapy, or in combination with at least one other anticancer therapy.